\(
\def\WIPO{World Intellectual Property Organisation}
\)
Форматы
| Формат | |
|---|---|
| BibTeX | |
| MARCXML | |
| TextMARC | |
| MARC | |
| DataCite | |
| DublinCore | |
| EndNote | |
| NLM | |
| RefWorks | |
| RIS |
Полное описание
Название
Not all pharma IP law is transferable.
Тип объекта
Journal article
Описание
GB 139 May 2010, p. 96; [28] cm
ISSN
2044-7175
Альтернативный идентификационный номер
GB 139
Резюме
The battle for supremacy between Europe and the US in the fields of pharmaceutical R&D and innovation has pointlessly flared up once again. A recently published survey by international intellectual property specialists Marks & Clerk indicates that the US IP system is viewed as being more favourable to innovation and that President Obama's recently passed healthcare reforms are proving to be increasingly palatable for big pharma.
Опубликовано
London, England: Informa, U.K. 2010.
Язык(и)
eng
Запись имеется в